Gut Bacteria Help Melanoma Patients Respond to Immunotherapy Again
A Phase 1b trial shows a daily probiotic capsule may restore immunotherapy response in advanced melanoma patients who had stopped responding.
Summary
A UK-led clinical trial has found that a microbiome-based therapy called MB097 — a daily capsule containing nine bacterial strains — may help advanced melanoma patients overcome resistance to immunotherapy. The MELODY-1 Phase 1b trial enrolled 41 patients across four countries who had stopped responding to KEYTRUDA, a leading immune checkpoint inhibitor. Researchers found MB097 was safe, well-tolerated, and successfully established itself in patients' gut microbiomes. Early signs suggest it may reactivate immune responses against tumors. This trial marks a meaningful step in moving microbiome medicine from wellness culture into real clinical oncology, reinforcing the idea that gut bacteria play a direct role in how the immune system fights disease and ages.
Detailed Summary
The gut microbiome is emerging as a serious player in cancer treatment, and new clinical trial data from Microbiotica offers some of the clearest human evidence yet. The MELODY-1 Phase 1b trial tested MB097, a capsule containing nine selected bacterial strains, in 41 advanced melanoma patients who had developed primary resistance to anti-PD-1 immunotherapy — a class of drugs that normally helps the immune system attack tumors.
The core finding is encouraging: MB097 was safe, caused no serious adverse events, and successfully engrafted in patients' gut microbiomes. Critically, early efficacy signals suggest the therapy may help some patients regain responsiveness to KEYTRUDA (pembrolizumab), the immunotherapy drug they had previously stopped responding to. Half the participants received the antibiotic vancomycin beforehand to clear microbial space, a strategy analogous to preparing soil before planting.
The science behind this approach rests on a growing body of evidence showing that gut bacteria are not passive bystanders. They actively modulate immune signaling, inflammation, and drug metabolism. In oncology, this means the microbiome may function as a biological gatekeeper — influencing whether immune checkpoint inhibitors can do their job at all. Reshaping the microbiome, the hypothesis goes, can shift the immune system into a more responsive state.
For longevity researchers, the implications extend beyond cancer. The same microbiome pathways that influence immune checkpoint response also intersect with inflammaging, metabolic health, and immune senescence — core mechanisms of biological aging. A therapy that can tune immune activity via the gut has potential relevance well beyond oncology.
Important caveats apply. MELODY-1 is a Phase 1b trial, primarily designed to assess safety rather than prove efficacy. The sample size is small at 41 patients, and full efficacy data awaits larger Phase 2 or 3 trials. These results are preliminary and have not yet been published in a peer-reviewed journal.
Key Findings
- MB097, a 9-strain bacterial capsule, was safe and well-tolerated in advanced melanoma patients with no serious adverse events.
- The bacterial strains successfully engrafted in patients' gut microbiomes, establishing a stable therapeutic presence.
- Early signals suggest MB097 may help restore immunotherapy response in patients with primary anti-PD-1 resistance.
- Antibiotic pretreatment with vancomycin was used in half of patients to improve microbial engraftment conditions.
- Gut microbiome modulation represents a potential strategy to overcome immunotherapy resistance in hard-to-treat cancers.
Methodology
This is a news report summarizing announced Phase 1b clinical trial results from Microbiotica, published by Longevity.Technology, a credible longevity-focused outlet. The evidence basis is industry-announced trial data from the MELODY-1 study, which has not yet been confirmed as peer-reviewed or published in a primary journal. Quotes from a named clinical investigator at Cambridge University Hospitals add credibility, but independent verification of full data is warranted.
Study Limitations
MELODY-1 is a Phase 1b trial focused on safety, not powered to confirm efficacy — early positive signals are hypothesis-generating, not conclusive. The trial enrolled only 41 patients, limiting statistical confidence in any efficacy observations. Full data have not yet been peer-reviewed or published, so independent scientific scrutiny of the results is still pending.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.